Applied Therapeutics (NASDAQ:APLT – Get Free Report) and Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.
Institutional & Insider Ownership
98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Applied Therapeutics and Akebia Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Applied Therapeutics | $1.00 million | 15.86 | -$105.62 million | ($0.10) | -1.03 |
| Akebia Therapeutics | $197.20 million | 0.63 | -$5.34 million | ($0.16) | -2.80 |
Akebia Therapeutics has higher revenue and earnings than Applied Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Applied Therapeutics and Akebia Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Applied Therapeutics | N/A | -340.84% | -175.00% |
| Akebia Therapeutics | -22.60% | -156.59% | -11.53% |
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Applied Therapeutics and Akebia Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Applied Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
| Akebia Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
Applied Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 870.87%. Akebia Therapeutics has a consensus target price of $3.50, indicating a potential upside of 680.21%. Given Applied Therapeutics’ higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Akebia Therapeutics.
Volatility & Risk
Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500.
About Applied Therapeutics
Applied Therapeutics is a biotechnology company focused on developing small-molecule medicines for rare metabolic and other serious diseases. Founded in 2016, the company is based in New York and was founded by Shoshana Shendelman, who has served as its chief executive officer. The company’s pipeline has centered on govorestat, an investigational inhibitor of the enzyme aldose reductase. Applied Therapeutics has studied the drug in conditions including classic galactosemia, SORD deficiency and PMM2-CDG, disorders that can affect multiple body systems and have limited treatment options.
About Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for people affected by kidney disease. Founded in 2007 and based in Cambridge, Massachusetts, the company’s work has centered on anemia and other complications associated with chronic kidney disease. Its products include Vafseo (vadadustat), an oral treatment for anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and Auryxia (ferric citrate).
Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
